ID   BMX_HUMAN               Reviewed;         675 AA.
AC   P51813; A6NIH9; O60564; Q12871;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=Cytoplasmic tyrosine-protein kinase BMX;
DE            EC=2.7.10.2;
DE   AltName: Full=Bone marrow tyrosine kinase gene in chromosome X protein;
DE   AltName: Full=Epithelial and endothelial tyrosine kinase;
DE            Short=ETK;
DE   AltName: Full=NTK38;
GN   Name=BMX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7970727;
RA   Tamagnone L., Lahtinen I., Mustonen T., Virtaneva K., Francis F.,
RA   Muscatelli F., Alitalo R.P., Smith C.I., Larsson C., Alitalo K.;
RT   "BMX, a novel nonreceptor tyrosine kinase gene of the BTK/ITK/TEC/TXK
RT   family located in chromosome Xp22.2.";
RL   Oncogene 9:3683-3688(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INDUCTION.
RC   TISSUE=Prostate;
RX   PubMed=9520419; DOI=10.1073/pnas.95.7.3644;
RA   Qiu Y., Robinson D., Pretlow T., Kung H.-J.;
RT   "Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an
RT   effector of phosphatidylinositol 3'-kinase and is involved in
RT   interleukin 6-induced neuroendocrine differentiation of prostate
RT   cancer cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:3644-3649(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 207-220 AND 223-236, AND PHOSPHORYLATION AT
RP   TYR-216 AND TYR-224.
RX   PubMed=12573241; DOI=10.1016/S1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 536-599.
RC   TISSUE=Blood;
RA   Fuortes M.;
RL   Thesis (1994), Cornell University, United States.
RN   [8]
RP   PHOSPHORYLATION AT TYR-566, MUTAGENESIS OF TYR-566, FUNCTION, AND
RP   INTERACTION WITH STAT3.
RX   PubMed=10688651; DOI=10.1128/MCB.20.6.2043-2054.2000;
RA   Tsai Y.T., Su Y.H., Fang S.S., Huang T.N., Qiu Y., Jou Y.S.,
RA   Shih H.M., Kung H.J., Chen R.H.;
RT   "Etk, a Btk family tyrosine kinase, mediates cellular transformation
RT   by linking Src to STAT3 activation.";
RL   Mol. Cell. Biol. 20:2043-2054(2000).
RN   [9]
RP   INDUCTION, INTERACTION WITH PTK2/FAK1, ENZYME REGULATION, AND
RP   FUNCTION.
RX   PubMed=11331870; DOI=10.1038/35074500;
RA   Chen R., Kim O., Li M., Xiong X., Guan J.L., Kung H.J., Chen H.,
RA   Shimizu Y., Qiu Y.;
RT   "Regulation of the PH-domain-containing tyrosine kinase Etk by focal
RT   adhesion kinase through the FERM domain.";
RL   Nat. Cell Biol. 3:439-444(2001).
RN   [10]
RP   DOMAIN, AND INTERACTION WITH CAV1.
RX   PubMed=11751885; DOI=10.1074/jbc.M108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T.,
RA   Smith C.I., Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase
RT   and Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [11]
RP   INTERACTION WITH RUFY1 AND RUFY2.
RX   PubMed=11877430; DOI=10.1074/jbc.M111933200;
RA   Yang J., Kim O., Wu J., Qiu Y.;
RT   "Interaction between tyrosine kinase Etk and a RUN-domain and FYVE-
RT   domain containing protein RUFY1. A possible role of Etk in regulation
RT   of vesicle trafficking.";
RL   J. Biol. Chem. 277:30219-30226(2002).
RN   [12]
RP   ENZYME REGULATION, PHOSPHORYLATION, FUNCTION, AND INTERACTION WITH
RP   TNFRSF1B.
RX   PubMed=12370298; DOI=10.1128/MCB.22.21.7512-7523.2002;
RA   Pan S., An P., Zhang R., He X., Yin G., Min W.;
RT   "Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase:
RT   role in endothelial cell migration and angiogenesis.";
RL   Mol. Cell. Biol. 22:7512-7523(2002).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BCAR1.
RX   PubMed=12832404; DOI=10.1074/jbc.M306438200;
RA   Abassi Y.A., Rehn M., Ekman N., Alitalo K., Vuori K.;
RT   "p130Cas Couples the tyrosine kinase Bmx/Etk with regulation of the
RT   actin cytoskeleton and cell migration.";
RL   J. Biol. Chem. 278:35636-35643(2003).
RN   [14]
RP   FUNCTION.
RX   PubMed=15788485; DOI=10.1152/ajpcell.00410.2004;
RA   Chau C.H., Clavijo C.A., Deng H.T., Zhang Q., Kim K.J., Qiu Y.,
RA   Le A.D., Ann D.K.;
RT   "Etk/Bmx mediates expression of stress-induced adaptive genes VEGF,
RT   PAI-1, and iNOS via multiple signaling cascades in different cell
RT   systems.";
RL   Am. J. Physiol. 289:C444-C454(2005).
RN   [15]
RP   PHOSPHORYLATION, ENZYME REGULATION, FUNCTION, AND INTERACTION WITH
RP   MYD88; PTK2/FAK1 AND TIRAP.
RX   PubMed=18292575; DOI=10.4049/jimmunol.180.5.3485;
RA   Semaan N., Alsaleh G., Gottenberg J.E., Wachsmann D., Sibilia J.;
RT   "Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the
RT   cross-talk between MyD88 and FAK pathways.";
RL   J. Immunol. 180:3485-3491(2008).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=11114746; DOI=10.1038/sj.onc.1203958;
RA   Qiu Y., Kung H.J.;
RT   "Signaling network of the Btk family kinases.";
RL   Oncogene 19:5651-5661(2000).
RN   [17]
RP   REVIEW ON FUNCTION.
RX   PubMed=11340625; DOI=10.1002/bies.1062;
RA   Smith C.I., Islam T.C., Mattsson P.T., Mohamed A.J., Nore B.F.,
RA   Vihinen M.;
RT   "The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx,
RT   Itk, Tec, Txk and homologs in other species.";
RL   Bioessays 23:436-446(2001).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=17624943; DOI=10.1111/j.1600-065X.2007.00534.x;
RA   Gomez-Rodriguez J., Readinger J.A., Viorritto I.C., Mueller K.L.,
RA   Houghtling R.A., Schwartzberg P.L.;
RT   "Tec kinases, actin, and cell adhesion.";
RL   Immunol. Rev. 218:45-64(2007).
RN   [19]
RP   STRUCTURE BY NMR OF 112-393.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human BMX SH2 domain and of the BTK motif
RT   of human cytoplasmic tyrosine-protein kinase BMX.";
RL   Submitted (OCT-2007) to the PDB data bank.
RN   [20]
RP   STRUCTURE BY NMR OF 291-393.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human bmx SH2 domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-284 AND TRP-670.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine kinase that plays central but
CC       diverse modulatory roles in various signaling processes involved
CC       in the regulation of actin reorganization, cell migration, cell
CC       proliferation and survival, cell adhesion, and apoptosis.
CC       Participates in signal transduction stimulated by growth factor
CC       receptors, cytokine receptors, G-protein coupled receptors,
CC       antigen receptors and integrins. Induces tyrosine phosphorylation
CC       of BCAR1 in response to integrin regulation. Activation of BMX by
CC       integrins is mediated by PTK2/FAK1, a key mediator of integrin
CC       signaling events leading to the regulation of actin cytoskeleton
CC       and cell motility. Plays a critical role in TNF-induced
CC       angiogenesis, and implicated in the signaling of TEK and FLT1
CC       receptors, 2 important receptor families essential for
CC       angiogenesis. Required for the phosphorylation and activation of
CC       STAT3, a transcription factor involved in cell differentiation.
CC       Also involved in interleukin-6 (IL6) induced differentiation.
CC       Plays also a role in programming adaptive cytoprotection against
CC       extracellular stress in different cell systems, salivary
CC       epithelial cells, brain endothelial cells, and dermal fibroblasts.
CC       May be involved in regulation of endocytosis through its
CC       interaction with an endosomal protein RUFY1. May also play a role
CC       in the growth and differentiation of hematopoietic cells; as well
CC       as in signal transduction in endocardial and arterial endothelial
CC       cells. {ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:12370298, ECO:0000269|PubMed:12832404,
CC       ECO:0000269|PubMed:15788485, ECO:0000269|PubMed:18292575,
CC       ECO:0000269|PubMed:9520419}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- ENZYME REGULATION: TEK and vascular endothelial growth factor
CC       receptor 1 (FLT1) stimulate BMX tyrosine kinase activity (By
CC       similarity). Activated by integrins through the mediation of
CC       PTK2/FAK1. Activated by TNF through the mediation of TNFRSF1B.
CC       {ECO:0000250, ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:12370298, ECO:0000269|PubMed:18292575}.
CC   -!- SUBUNIT: Interacts with BCAR1, CAV1, MYD88, PTK2/FAK1, RUFY1,
CC       RUFY2, STAT3, TIRAP and TNFRSF1B. {ECO:0000269|PubMed:10688651,
CC       ECO:0000269|PubMed:11331870, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:11877430, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:12832404, ECO:0000269|PubMed:18292575}.
CC   -!- INTERACTION:
CC       P11309:PIM1; NbExp=4; IntAct=EBI-696657, EBI-696621;
CC       P40763:STAT3; NbExp=6; IntAct=EBI-696657, EBI-518675;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12832404}.
CC       Note=Localizes to the edges of spreading cells when complexed with
CC       BCAR1.
CC   -!- TISSUE SPECIFICITY: Highly expressed in cells with great migratory
CC       potential, including endothelial cells and metastatic carcinoma
CC       cell lines.
CC   -!- INDUCTION: Activated by IL6/interleukin-6 through
CC       phosphatidylinositol 3-kinase (PI3-kinase) pathway. It is likely
CC       that activation occurs through binding of phosphoinositides to the
CC       PH domain. {ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:9520419}.
CC   -!- DOMAIN: SH2 domain mediates interaction with RUFY1.
CC       {ECO:0000269|PubMed:11751885}.
CC   -!- PTM: Phosphorylated in response to protein I/II and to LPS.
CC       Phosphorylation at Tyr-566 by SRC and by autocatalysis leads to
CC       activation and is required for STAT3 phosphorylation by BMX.
CC       {ECO:0000269|PubMed:10688651, ECO:0000269|PubMed:12370298,
CC       ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:18292575}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC08966.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X83107; CAA58169.1; -; mRNA.
DR   EMBL; AF045459; AAC08966.1; ALT_INIT; mRNA.
DR   EMBL; AC097625; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471074; EAW98889.1; -; Genomic_DNA.
DR   EMBL; BC016652; AAH16652.1; -; mRNA.
DR   EMBL; U08341; AAA17744.1; -; mRNA.
DR   CCDS; CCDS14168.1; -.
DR   PIR; S60612; S60612.
DR   RefSeq; NP_001307795.1; NM_001320866.1.
DR   RefSeq; NP_001712.1; NM_001721.6.
DR   RefSeq; NP_975010.1; NM_203281.2.
DR   UniGene; Hs.495731; -.
DR   PDB; 2EKX; NMR; -; A=291-393.
DR   PDB; 2YS2; NMR; -; A=113-149.
DR   PDB; 3SXR; X-ray; 2.40 A; A/B=411-675.
DR   PDB; 3SXS; X-ray; 1.89 A; A=411-675.
DR   PDBsum; 2EKX; -.
DR   PDBsum; 2YS2; -.
DR   PDBsum; 3SXR; -.
DR   PDBsum; 3SXS; -.
DR   ProteinModelPortal; P51813; -.
DR   SMR; P51813; -.
DR   BioGrid; 107128; 27.
DR   IntAct; P51813; 12.
DR   MINT; MINT-1433284; -.
DR   STRING; 9606.ENSP00000308774; -.
DR   BindingDB; P51813; -.
DR   ChEMBL; CHEMBL3834; -.
DR   GuidetoPHARMACOLOGY; 1942; -.
DR   iPTMnet; P51813; -.
DR   PhosphoSitePlus; P51813; -.
DR   BioMuta; BMX; -.
DR   DMDM; 1705489; -.
DR   MaxQB; P51813; -.
DR   PaxDb; P51813; -.
DR   PeptideAtlas; P51813; -.
DR   PRIDE; P51813; -.
DR   DNASU; 660; -.
DR   Ensembl; ENST00000342014; ENSP00000340082; ENSG00000102010.
DR   Ensembl; ENST00000348343; ENSP00000308774; ENSG00000102010.
DR   Ensembl; ENST00000357607; ENSP00000350224; ENSG00000102010.
DR   GeneID; 660; -.
DR   KEGG; hsa:660; -.
DR   UCSC; uc004cww.3; human.
DR   CTD; 660; -.
DR   DisGeNET; 660; -.
DR   GeneCards; BMX; -.
DR   HGNC; HGNC:1079; BMX.
DR   HPA; CAB032495; -.
DR   HPA; HPA001048; -.
DR   MIM; 300101; gene.
DR   neXtProt; NX_P51813; -.
DR   OpenTargets; ENSG00000102010; -.
DR   PharmGKB; PA25389; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000119011; -.
DR   HOGENOM; HOG000233859; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P51813; -.
DR   KO; K08896; -.
DR   OMA; EYISNGC; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P51813; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   SignaLink; P51813; -.
DR   SIGNOR; P51813; -.
DR   ChiTaRS; BMX; human.
DR   EvolutionaryTrace; P51813; -.
DR   GeneWiki; BMX_(gene); -.
DR   GenomeRNAi; 660; -.
DR   PMAP-CutDB; P51813; -.
DR   PRO; PR:P51813; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102010; -.
DR   CleanEx; HS_BMX; -.
DR   Genevisible; P51813; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0032587; C:ruffle membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0097194; P:execution phase of apoptosis; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:InterPro.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0001865; P:NK T cell differentiation; IBA:GO_Central.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR028840; BMX.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   PANTHER; PTHR24418:SF296; PTHR24418:SF296; 1.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell adhesion;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Kinase;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; SH2 domain; Stress response; Transferase;
KW   Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   CHAIN         1    675       Cytoplasmic tyrosine-protein kinase BMX.
FT                                /FTId=PRO_0000088063.
FT   DOMAIN        4    111       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN      296    392       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      417    675       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING     113    149       Btk-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00432}.
FT   NP_BIND     423    431       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       596    603       CAV1-binding.
FT   COMPBIAS    251    255       Poly-Ser.
FT   COMPBIAS    282    285       Poly-Ser.
FT   COMPBIAS    286    289       Poly-Glu.
FT   ACT_SITE    536    536       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       121    121       Zinc. {ECO:0000250}.
FT   METAL       132    132       Zinc. {ECO:0000250}.
FT   METAL       133    133       Zinc. {ECO:0000250}.
FT   METAL       143    143       Zinc. {ECO:0000250}.
FT   BINDING     445    445       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     216    216       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12573241}.
FT   MOD_RES     224    224       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12573241}.
FT   MOD_RES     566    566       Phosphotyrosine; by SRC and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:10688651}.
FT   VARIANT     284    284       S -> L (in dbSNP:rs35353387).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041674.
FT   VARIANT     670    670       R -> W (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041675.
FT   MUTAGEN     566    566       Y->F: Abolishes almost completely the
FT                                SRC-induced phosphorylation of BMX.
FT                                {ECO:0000269|PubMed:10688651}.
FT   CONFLICT    207    207       P -> G (in Ref. 6; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    597    597       A -> S (in Ref. 7; AAA17744).
FT                                {ECO:0000305}.
FT   STRAND      129    133       {ECO:0000244|PDB:2YS2}.
FT   STRAND      136    139       {ECO:0000244|PDB:2YS2}.
FT   STRAND      294    297       {ECO:0000244|PDB:2EKX}.
FT   HELIX       303    312       {ECO:0000244|PDB:2EKX}.
FT   STRAND      318    323       {ECO:0000244|PDB:2EKX}.
FT   STRAND      330    334       {ECO:0000244|PDB:2EKX}.
FT   STRAND      347    350       {ECO:0000244|PDB:2EKX}.
FT   STRAND      359    362       {ECO:0000244|PDB:2EKX}.
FT   HELIX       370    379       {ECO:0000244|PDB:2EKX}.
FT   STRAND      383    385       {ECO:0000244|PDB:2EKX}.
FT   HELIX       414    416       {ECO:0000244|PDB:3SXS}.
FT   STRAND      417    426       {ECO:0000244|PDB:3SXS}.
FT   STRAND      429    436       {ECO:0000244|PDB:3SXS}.
FT   TURN        437    439       {ECO:0000244|PDB:3SXS}.
FT   STRAND      440    447       {ECO:0000244|PDB:3SXS}.
FT   HELIX       454    466       {ECO:0000244|PDB:3SXS}.
FT   STRAND      475    479       {ECO:0000244|PDB:3SXS}.
FT   STRAND      481    490       {ECO:0000244|PDB:3SXS}.
FT   HELIX       497    504       {ECO:0000244|PDB:3SXS}.
FT   HELIX       505    507       {ECO:0000244|PDB:3SXS}.
FT   HELIX       510    529       {ECO:0000244|PDB:3SXS}.
FT   STRAND      532    536       {ECO:0000244|PDB:3SXS}.
FT   HELIX       539    541       {ECO:0000244|PDB:3SXS}.
FT   STRAND      542    544       {ECO:0000244|PDB:3SXS}.
FT   STRAND      550    552       {ECO:0000244|PDB:3SXS}.
FT   TURN        555    557       {ECO:0000244|PDB:3SXR}.
FT   STRAND      558    560       {ECO:0000244|PDB:3SXS}.
FT   STRAND      566    568       {ECO:0000244|PDB:3SXS}.
FT   HELIX       576    578       {ECO:0000244|PDB:3SXS}.
FT   HELIX       581    586       {ECO:0000244|PDB:3SXS}.
FT   STRAND      587    590       {ECO:0000244|PDB:3SXS}.
FT   HELIX       593    606       {ECO:0000244|PDB:3SXS}.
FT   TURN        607    609       {ECO:0000244|PDB:3SXS}.
FT   TURN        612    615       {ECO:0000244|PDB:3SXS}.
FT   HELIX       618    626       {ECO:0000244|PDB:3SXS}.
FT   HELIX       639    647       {ECO:0000244|PDB:3SXS}.
FT   HELIX       653    655       {ECO:0000244|PDB:3SXS}.
FT   HELIX       659    666       {ECO:0000244|PDB:3SXS}.
FT   HELIX       667    669       {ECO:0000244|PDB:3SXS}.
SQ   SEQUENCE   675 AA;  78011 MW;  CB22382A3BD02599 CRC64;
     MDTKSILEEL LLKRSQQKKK MSPNNYKERL FVLTKTNLSY YEYDKMKRGS RKGSIEIKKI
     RCVEKVNLEE QTPVERQYPF QIVYKDGLLY VYASNEESRS QWLKALQKEI RGNPHLLVKY
     HSGFFVDGKF LCCQQSCKAA PGCTLWEAYA NLHTAVNEEK HRVPTFPDRV LKIPRAVPVL
     KMDAPSSSTT LAQYDNESKK NYGSQPPSSS TSLAQYDSNS KKIYGSQPNF NMQYIPREDF
     PDWWQVRKLK SSSSSEDVAS SNQKERNVNH TTSKISWEFP ESSSSEEEEN LDDYDWFAGN
     ISRSQSEQLL RQKGKEGAFM VRNSSQVGMY TVSLFSKAVN DKKGTVKHYH VHTNAENKLY
     LAENYCFDSI PKLIHYHQHN SAGMITRLRH PVSTKANKVP DSVSLGNGIW ELKREEITLL
     KELGSGQFGV VQLGKWKGQY DVAVKMIKEG SMSEDEFFQE AQTMMKLSHP KLVKFYGVCS
     KEYPIYIVTE YISNGCLLNY LRSHGKGLEP SQLLEMCYDV CEGMAFLESH QFIHRDLAAR
     NCLVDRDLCV KVSDFGMTRY VLDDQYVSSV GTKFPVKWSA PEVFHYFKYS SKSDVWAFGI
     LMWEVFSLGK QPYDLYDNSQ VVLKVSQGHR LYRPHLASDT IYQIMYSCWH ELPEKRPTFQ
     QLLSSIEPLR EKDKH
//
